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In Reply Dr Felson raises 3 points with regard to a potential role
of confounding by indication to explain our findings.1
First, he comments on the lack of information on severity
of comorbidities. While our propensity score–matched analy-
sis was not able to account for severity level of all covariates,
some were incorporated (eg, stages of chronic kidney dis-
ease). Nevertheless, a comprehensive propensity score–
matched study design with many covariates included tends
to balance even unmeasured and unadjusted variables
(through their associations with adjusted variables). As such,
we expect the unmeasured and unadjustable covariates, such
as levels of disease severity, also to be balanced after a com-
prehensive propensity score matching. Prompted by this
comment, we conducted propensity score matching without
incorporating stages of chronic kidney disease and found the
stages were well balanced among all comparison groups,
although they were not included in the propensity score cre-
ation. This supports the expectation that other comorbidity
severities should be balanced despite not being included in
the propensity score generation.
Second, Felson was concerned about the short duration of
tramadol use and the intention-to-treat analysis. As we re-
ported, “the mean (range) treatment duration of a prescrip-
tion for tramadol was 22 (5-67) days….” As such, the mean du-
ration of tramadol use was 110 days, not 22 days. Furthermore,
in addition to the intention-to-treat analysis, we conducted an
as-treated analysis by censoring follow-up at the time of dis-
continuation of a patient’s medication and found the effect es-
timates to be stronger than in the intention-to-treat analysis
(Table 3 in the article).1
Third, Felson raised the issue of the effectiveness of
excluding patients with cancer at baseline. As acknowl-
edged in the article, “it is possible that some participants
were experiencing pain from undetected early-stage cancer
and therefore were given stronger pain medication to
relieve the symptoms prior to cancer diagnosis (ie, proto-
pathic bias).” However, we additionally excluded cases of
cancer (including all cancer deaths) that occurred within 6
months or 1 year of the start of follow-up and found no
material difference in our results (Table 3 in the article), as
was done in previous studies.2,3
All in all, we adopted a state-of-the-art approach to mini-
mize the potential biases with multiple sensitivity analyses,
and our interpretation was balanced. The finding of higher mor-
tality among patients receiving tramadol than patients receiv-
ing NSAIDs raises a potential safety concern for tramadol use
in patients with osteoarthritis. As we concluded, “however,
these findings may be susceptible to confounding by indica-
tion, and further research is needed to determine if the asso-
ciation is causal.”1
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Dietary Cholesterol or Egg Consumption
and Cardiovascular Outcomes
To the Editor Based on an analysis of 6 prospective cohorts,
Dr Zhong and colleagues1 concluded that “higher consump-
tion of dietary cholesterol or eggs was significantly associ-
ated with higher risk of incident CVD [cardiovascular dis-
ease] and all-cause mortality in a dose-response manner” and
noted these findings should be considered “in the develop-
ment of dietary guidelines and updates.” At issue is whether
their findings, which differ from some previously published
meta-analyses on this topic,2,3 are sufficiently robust to be con-
sidered in guidelines.
Baseline characteristics of study participants, according to
5 levels of reported dietary cholesterol or egg intake, were pre-
sented in eTables 1 and 2 in the online supplement. Individu-
als with the lowest cholesterol intake reported exceptionally
low energy intake (902 kcal/d), despite having a similar body
mass index as the others. Less alcohol consumption and cur-
rent smoking and greater use of antihypertensive, lipid-
lowering, and hormone replacement medications were also as-
sociated with lower cholesterol or egg intake.
Based on these differences, we believe those reporting
less cholesterol or egg intake may be more health conscious,
potentially resulting in general underreporting of total
food intake and a more specific bias of underreporting
egg intake (during baseline data collection for 5 of 6 study
cohorts, low cholesterol or egg intake was recommended4).
Individuals with greater health consciousness may also
have been more likely to adhere to prescribed medications
and engage in other healthful behaviors that contributed to
improved outcomes.5
Although the authors adjusted for measured characteris-
tics that may serve as proxies for health consciousness, such
Letters
466 JAMA August 6, 2019 Volume 322, Number 5 (Reprinted) jama.com
© 2019 American Medical Association. All rights reserved.
as baseline alcohol and tobacco use, health consciousness is
a latent concept, and it is not clear that the variables adjusted
for were sufficient to control for all confounding. In these situ-
ations, it is often helpful to use falsification tests, which seek
to determine if an association that should not be present af-
ter sufficient adjustment is in fact present. In this case, exam-
ining whether individuals reporting lower dietary choles-
terol or egg intake had higher rates of recommended cancer
screenings or immunizations, adjusting for the same factors
as in the primary outcome models, could serve as a good fal-
sification test. Dietary cholesterol should not have an effect
on completing colorectal cancer screening, for example, so if
an association were observed, it would suggest residual con-
founding by a factor, such as health consciousness, that could
serve as a common cause of both lower reported cholesterol
or egg consumption and fewer cardiovascular events.
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In Reply Dr Keyserling and colleagues commented that the
observed associations of dietary cholesterol or egg consump-
tion with incident cardiovascular disease and all-cause mor-
tality in our study might be partly attributable to residual
confounding due to unmeasured health consciousness.1
We agree that by adjusting for several available proxies for
health consciousness, we may not have fully eliminated the
related confounding.
Their argument originated from a result presented in
eTable 1 in the online supplement. A small subgroup (n = 1989
[6.7%]) who consumed the lowest amount of dietary choles-
terol (<100 mg/d) reported very low energy intake with a me-
dian of approximately 900 kcal/d. There are several reasons
for this. First, the proportion of women in this small sub-
group (66.4%) was the highest among all the 5 subgroups. It
is known that women, on average, consume less total energy
than men. In our data set, the median energy intake was 1545
(interquartile range, 1165-2027) kcal/d in women and 1860 (in-
terquartile range, 1399-2502) kcal/d in men. Second, the mean
age of this small subgroup (57.7 years) was the oldest among
all the 5 subgroups. Older adults (≥60 years) generally have con-
siderably lower energy intake compared with younger adults
(20-59 years).2 Third, dietary cholesterol is found in all foods
of animal source such as meat, poultry, eggs, dairy products,
fish, and shellfish. People who consume only a small amount
of these foods may be likely to have a relatively lower energy
intake compared with those who consume more. Fourth, as
pointed out by Keyserling and colleagues, underreporting is
likely for self-reported dietary intake. However, we do not know
who underreported for what reasons.
Our pooling project was originally created to study long-
term risks and development patterns of cardiovascular dis-
ease over the life course in adults. Our pooled data set did not
include variables that are likely unrelated to dietary choles-
terol or egg consumption, such as cancer screenings, immu-
nizations, trauma, and respiratory infection. Therefore, we are
unable to perform falsification testing. Nonetheless, in
a sensitivity analysis, we restricted the entire study sample
(N = 29 615) to nonsmokers with body mass index less than 25
and little alcohol intake (<0.5 g/d), who may be more health
conscious than others. A nonsignificant association with in-
cident cardiovascular disease in the same direction as the main
analysis was observed for dietary cholesterol consumption (ad-
justed hazard ratio per 300 mg/d, 1.40 [95% CI, 0.96-2.05]) and
for egg consumption (adjusted hazard ratio per half an egg per
day, 1.20 [95% CI, 0.99-1.46]). The statistical nonsignificance
was probably due to the low power (n = 2549 [8.6%]).
Future nutritional epidemiologic studies that deliber-
ately include data collection intended for falsification testing
are encouraged. It should be proposed a priori in the study de-
sign stage to avoid post hoc data mining. However, the ab-
sence of an association between a primary exposure and an un-
related outcome might offer indirect support for but certainly
not guarantee the existence of an association between a pri-
mary exposure and a primary outcome.3
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